Novo Nordisk committed up to $2.1 billion to license Vivtex’s gastrointestinal screening and formulation platform as part of a program to develop oral peptide and protein therapeutics for obesity, diabetes and related metabolic diseases. Under the agreement, Novo will lead global development, regulatory filings, manufacturing and commercialization after the research stage; Vivtex is eligible for upfront, research funding and milestone payments plus royalties. Vivtex, an MIT spin‑out, uses high‑throughput GI assays and AI to identify formulations that can traverse intestinal barriers; the partnership aims to convert injectable biologics into oral regimens. Vivtex co‑founders and MIT‑connected scientists join industry veterans to advance formulations that could change dosing convenience and adherence for chronic metabolic indications. Novo’s commitment signals renewed industry focus on oral biologics and validates Vivtex’s platform as a potential enabler of non‑injectable peptide drugs.